3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
14
Observational
1
Sponsor
Cancer Type
Gastrointestinal
26
Thoracic
20
Tumor-Agnostic
3
Breast
2
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Triple Negative Breast Neoplasms
1
Melanoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Blood Specimen Collection
22
Surveys and Questionnaires
19
Nivolumab
14
Ipilimumab
12
pembrolizumab
11
Gene Expression Profiling
11
Biopsy
10
trametinib
9
dabrafenib
8
Flow Cytometry
8
Specimen Handling
7
Polymerase Chain Reaction
7
Tomography, Optical Coherence
6
Therapeutics
6
Immunohistochemistry
6
Imiquimod
6
Amplified Fragment Length Polymorphism Analysis
6
Watchful Waiting
5
Psychiatric Rehabilitation
5
Immunotherapy
5
Data Collection
5
3-ingenyl angelate
5
Mohs Surgery
4
Microarray Analysis
4
Interviews as Topic
4
Immunoenzyme Techniques
4
Drug Therapy
4
Dermoscopy
4
sonidegib
3
encorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Immune Checkpoint Inhibitors
×
Dermatologic
×
Clear all
NCT05037825
2022-04-27
PARADIGM
VastBiome
Recruiting
800 enrolled